{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:31:12Z","timestamp":1790155872435,"version":"4.0.1"},"reference-count":51,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>CMX157 is a lipid (1-0-hexadecyloxypropyl) conjugate of the acyclic nucleotide analog tenofovir (TFV) with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside\/nucleotide analog-resistant viruses. CMX157 was consistently &gt;300-fold more active than tenofovir against multiple viruses in several different cell systems. CMX157 was active against all major subtypes of HIV-1 and HIV-2 in fresh human peripheral blood mononuclear cells (PBMCs) and against all HIV-1 strains evaluated in monocyte-derived macrophages, with 50% effective concentrations (EC<jats:sub>50<\/jats:sub>s) ranging between 0.20 and 7.2 nM. The lower CMX157 EC<jats:sub>50<\/jats:sub>s can be attributed to better cellular uptake of CMX157, resulting in higher intracellular levels of the active antiviral anabolite, TFV-diphosphate (TFV-PP), inside target cells. CMX157 produced &gt;30-fold higher levels of TFV-PP in human PBMCs exposed to physiologically relevant concentrations of the compounds than did TFV. Unlike conventional prodrugs, including TFV disoproxil fumarate (Viread), CMX157 remains intact in plasma, facilitating uptake by target cells and decreasing relative systemic exposure to TFV. There was no detectable antagonism with CMX157 in combination with any marketed antiretroviral drug, and it possessed an excellent<jats:italic>in vitro<\/jats:italic>cytotoxicity profile. CMX157 is a promising clinical candidate to treat wild-type and antiretroviral drug-resistant HIV, including strains that fail to respond to all currently available nucleoside\/nucleotide reverse transcriptase inhibitors.<\/jats:p>","DOI":"10.1128\/aac.00068-10","type":"journal-article","created":{"date-parts":[[2010,5,4]],"date-time":"2010-05-04T01:57:40Z","timestamp":1272938260000},"page":"2901-2909","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":43,"title":["Development of Hexadecyloxypropyl Tenofovir (CMX157) for Treatment of Infection Caused by Wild-Type and Nucleoside\/Nucleotide-Resistant HIV"],"prefix":"10.1128","volume":"54","author":[{"given":"E. Randall","family":"Lanier","sequence":"first","affiliation":[{"name":"Chimerix Inc., Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger G.","family":"Ptak","sequence":"additional","affiliation":[{"name":"Southern Research Institute, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard M.","family":"Lampert","sequence":"additional","affiliation":[{"name":"Chimerix Inc., Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Keilholz","sequence":"additional","affiliation":[{"name":"Chimerix Inc., Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Hartman","sequence":"additional","affiliation":[{"name":"ImQuest BioSciences, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Robert W.","family":"Buckheit","sequence":"additional","affiliation":[{"name":"ImQuest BioSciences, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie K.","family":"Mankowski","sequence":"additional","affiliation":[{"name":"Southern Research Institute, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Osterling","sequence":"additional","affiliation":[{"name":"Southern Research Institute, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrick R.","family":"Almond","sequence":"additional","affiliation":[{"name":"Chimerix Inc., Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Painter","sequence":"additional","affiliation":[{"name":"Chimerix Inc., Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1994.10.1581"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.59.2.284-291.1986"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1991.7.295"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.64.10.4735-4742.1990"},{"key":"e_1_3_2_6_2","first-page":"181","volume":"45","year":"1996","unstructured":"CDC. 1996. Persistent lack of detectable HIV-1 anitbody in a person with HIV infection. MMWR Morb. Mortal. Wkly. Rep.45:181-185.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.71.5.3932-3939.1997"},{"key":"e_1_3_2_8_2","first-page":"42","volume":"6","year":"2001","unstructured":"Dupnik, K., M. Gonzales, and R. Shafer. 2001. Most multidrug-resistant HIV-1 reverse transcriptase clones in plasma encode functional reverse transcriptase enzymes. Antivir. Ther.6(Suppl.):42.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/315024"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1994.10.1359"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f366ff"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3014648"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4049\/jimmunol.148.2.422","volume":"148","year":"1992","unstructured":"Gendelman, H. E., L. M. Baca, C. A. Kubrak, P. Genis, S. Burrous, R. M. Friedman, D. Jacobs, and M. S. Meltzer. 1992. Induction of IFN-alpha in peripheral blood mononuclear cells by HIV-infected monocytes. Restricted antiviral activity of the HIV-induced IFN. J. Immunol.148:422-429.","journal-title":"J. Immunol."},{"key":"e_1_3_2_15_2","first-page":"475","volume":"3","year":"1989","unstructured":"Gendelman, H. E., J. M. Orenstein, L. M. Baca, B. Weiser, H. Burger, D. C. Kalter, and M. S. Meltzer. 1989. The macrophage in the persistence and pathogenesis of HIV infection. AIDS3:475-495.","journal-title":"AIDS"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.167.4.1428"},{"key":"e_1_3_2_17_2","unstructured":"Gilead Sciences Inc. 2008. Viread (tenofovir disoproxyl fumurate) tablets prescribing information. http:\/\/www.gilead.com\/pdf\/viread_pi.pdf ."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/427192"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)82446-X"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050158"},{"key":"e_1_3_2_21_2","first-page":"138","volume":"17","year":"2009","unstructured":"Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Gunthard, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2009. Update of the drug resistance mutations in HIV-1: December 2009. Top. HIV Med.17:138-145.","journal-title":"Top. HIV Med."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31815e7478"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3646751"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/528802"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01559-08"},{"key":"e_1_3_2_26_2","unstructured":"Proceedings of the 16th Conference on Retrovirus and Opportunistic Infections Montreal Canada 2009"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.69.9.5640-5649.1995"},{"key":"e_1_3_2_28_2","unstructured":"HIV chemotherapy 2005"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/381784"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2008.12.002"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/332469a0"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1987.3.283"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.7.5425-5432.1998"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00460-07"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2004.06.008"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.2.437-443.2004"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.920-928.2000"},{"key":"e_1_3_2_38_2","unstructured":"Retroviruses of human AIDS and related animal diseases 1988"},{"key":"e_1_3_2_39_2","first-page":"1472","volume":"2","year":"1984","unstructured":"Popovic, M., E. Read-Connole, and R. C. Gallo. 1984. T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet2:1472-1473.","journal-title":"Lancet"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6200935"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(90)90001-N"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01324-07"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/313277a0"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00251-06"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1086\/514491"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000248351.10383.b7"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.64.10.5177-5182.1990"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199901140-00012"},{"key":"e_1_3_2_49_2","first-page":"122","volume":"16","year":"2008","unstructured":"Szczech, L. A. 2008. Renal dysfunction and tenofovir toxicity in HIV-infected patients. Top. HIV Med.16:122-126.","journal-title":"Top. HIV Med."},{"key":"e_1_3_2_50_2","unstructured":"Preclinical safety evaluation of CMX157: a lipid-conjugated nucleotide analog for treatment of HIV. 2010"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.8.3097"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/135965350601100209","volume":"11","year":"2006","unstructured":"White, K. L., J. M. Chen, J. Y. Feng, N. A. Margot, J. K. Ly, A. S. Ray, H. L. MacArthur, M. J. McDermott, S. Swaminathan, and M. D. Miller. 2006. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir. Ther.11:155-163.","journal-title":"Antivir. Ther."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00068-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00068-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T01:00:17Z","timestamp":1685581217000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00068-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1128\/AAC.00068-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.00068-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"2010-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-04-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}